-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Whitehawk Therapeutics Presents Preclinical Data For HWK-007, HWK-016 And HWK-206 Next-Generation ADC Portfolio At AACR 2026, Showing Tumor Regressions At Low Single-Digit Mg/Kg Doses

Benzinga·04/20/2026 08:29:23
Listen to the news
  • Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform
  • Tumor regressions observed across various cancer models at low single‑digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC)
  • Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026